Laboratorios Syntex SA (later Syntex Laboratories, Inc.) was a pharmaceutical company formed in Mexico City in January 1944 by Russell Marker, Emeric Somlo, and Federico Lehmann to manufacture therapeutic steroids from the Mexican yams called cabeza de negro (Dioscorea mexicana) and Barbasco (Dioscorea composita).[1] The demand for barbasco by Syntex initiated the Mexican barbasco trade.[2]

As the American Chemistry Society later explained: “In early 1944, the new Mexican company was chartered and named Syntex, S.A. (‘Synthesis and Mexico’). Russell Marker, shortly thereafter, left Syntex on account of his ruthless cofounder.[3]

Luis E. Miramontes, George Rosenkranz and Carl Djerassi's successful synthesis of norethisterone (also known as norethindrone) — which was later proven to be an effective pregnancy inhibitor — led to an infusion of capital into Syntex and the Mexican steroid pharmaceutical industry.[4] George Rosenkranz and Carl Djerassi went on to synthesize cortisone from diosgenin, the same phytosteroid contained in Mexican yams used to synthesize progesterone and norethindrone. The synthesis was more economical than the previous Merck & Co. synthesis, which started with bile acids.

In 1959, Syntex moved its operating headquarters to Palo Alto, California, United States, and evolved into a transnational corporation. Its foreign scientists had become frustrated with bureaucratic delays on the part of the Mexican government in granting work visas and approving necessary imports of pharmaceutical materials for their work. After 1959, Syntex was incorporated in Panama; its administration, research and marketing were conducted from Palo Alto; its manufacturing of bulk steroid intermediates remained in Mexico; and it also manufactured finished drugs at plants in Puerto Rico and the Bahamas.[5]

Syntex agreed to be acquired by the Roche group in May 1994.[6] After the acquisition closed, Roche downsized Syntex's research and development facilities in the Stanford Research Park and finally shut down what was left of Syntex in September 2008.[7] In 2011, VMware moved into the former Syntex campus in Palo Alto.[8]

Prominent researchers

Birth control pill

Syntex submitted its compound to a laboratory in Madison, Wisconsin, for biological evaluation, and found it was the most active, orally-effective progestational hormone of its time. Syntex submitted a patent application in November 1951. In August 1953, G.D. Searle & Co. filed for a patent for the synthesis of the double-bond isomer 13 of norethindrone called noretynodrel. Noretynodrel is converted into norethisterone under acidic conditions, such as those in the human stomach, and the new patent did not infringe on the Syntex patent. Searle obtained approval to market noretynodrel before Syntex received its approval. By 1964 three companies, including Syntex, G.D. Searle, and Johnson & Johnson under the Ortho Pharmaceutical brand, were marketing 2-mg doses of the Syntex norethindrone.

Scientific misconduct

Syntex's submission of a fraudulent toxicology analysis of naproxen largely led to the Food and Drug Administration's uncovering of extensive scientific misconduct by Industrial Bio-Test Laboratories in 1976.[10][11][12][13]

References

  1. ^ Gereffi, Gary (1983). The Pharmaceutical Industry and Dependency in the Third World (2017 reprint ed.). Princeton University Press: Princeton. p. 83. ISBN 9781400886227. Retrieved 11 January 2021.
  2. ^ Laveaga, Gabriela Soto (2009). Jungle Laboratories: Mexican Peasants, National Projects, and the Making of the Pill. Durham: Duke University Press. p. 3. ISBN 9780822391968. Retrieved 11 January 2021.
  3. ^ "The 'Marker Degradation' & Creation of the Mexican Steroid Hormone Industry 1938–1945" (PDF). ACS.org. 1999.
  4. ^ McFadden, Robert D. (2019-06-23). "George Rosenkranz, 102, a Developer of the Birth Control Pill, Is Dead". The New York Times. ISSN 0362-4331. Retrieved 2023-02-03.
  5. ^ Gereffi, Gary (1983). The Pharmaceutical Industry and Dependency in the Third World (2017 reprint ed.). Princeton University Press: Princeton. p. 110. ISBN 9781400886227. Retrieved 11 January 2021.
  6. ^ Freudenheim, Milt (3 May 1994). "Roche Set To Acquire Syntex". New York Times.
  7. ^ Oremus, Will (September 2, 2008). "Roche confirms closing of Palo Alto complex". San Jose Mercury News.
  8. ^ Sheyner, Gennady (November 21, 2011). "VMware unveils plan for massive campus expansion". Palo Alto Online. Retrieved 3 September 2021.
  9. ^ Rosenkranz had fled Nazi Germany to avoid the eventual Holocaust; while in Cuba en route to South America, the Japanese attack on Pearl Harbor stranded him there. He was able to work there for the duration of the war.
  10. ^ Marshall, Eliot (1983-06-10). "The murky world of toxicity testing" (PDF). Science. 220 (4602): 1130–1132. Bibcode:1983Sci...220.1130M. doi:10.1126/science.6857237. PMID 6857237. Retrieved 2012-07-27.
  11. ^ "The Scandal in Chemical Testing". The New York Times. 1983-05-16. Retrieved 2012-07-27. The problem was discovered only by accident, when a Government official looking for something else pulled out a file of IBT data by mistake.
  12. ^ Merrell, Paul (Winter 1981). "The Industrial Bio-Test Caper" (PDF). NCAP News. 2 (3): 2–4. Archived from the original (PDF) on 2014-02-23. Retrieved 2012-08-05.
  13. ^ Foster, Douglas; Mark Dowie; Steve Hubbell; Irene Moosen; Peter Waldman; Center for Investigative Reporting (June 1982). "Poisoned Research". Mother Jones. 7 (5): 38–40, 42–43, 45–48. Retrieved 2012-07-28.

Further reading

Categories